A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
Colorectal Cancer · Pancreatic Ductal Adenocarcinoma · Biliary Tract Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 220 (planned)
- Started
- Jun 20, 2024
- Main results expected
- Oct 16, 2029
- Fully finished
- Oct 16, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants Who Experience a Dose-limiting Toxicity (DLT)
Measured over: Up to approximately 4 weeks
Number of Participants Who Experience One or More Adverse Events (AEs)
Measured over: Up to approximately 63 months
Number of Participants who Discontinue Study Treatment due to an AE
Measured over: Up to approximately 63 months
Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR)
Measured over: Up to approximately 63 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06428409 · record last updated 2026-10-29 · checked 2026-11-09 15:47 UTC